The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Follow AbbVie UK

Tags

AbbVie Receives CHMP Positive Opinion for SKYRIZI™ ▼ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis in adults

Press Releases   •   Mar 01, 2019 12:13 GMT

CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission1-3

HUMIRA® (adalimumab) 80 mg/0.8 mL Presentation intended as an Alternative Option for Therapy Induction and Maintenance Therapy is Now Available

Press Releases   •   Dec 03, 2018 09:25 GMT

• HUMIRA citrate-free 80 mg/0.8 mL formulation reduces the number of injections required to initiate HUMIRA therapy by half • Convenient 80 mg every other week dosing for patients that require dose escalation

Efforts to Improve Patient Safety and Care Recognised in National Health Awards

Efforts to Improve Patient Safety and Care Recognised in National Health Awards

Press Releases   •   Nov 20, 2018 15:27 GMT

South Tees NHS Foundation Trust, Lymphoma Action and Arthur’s Choice win 2018 AbbVie Big Ideas for Better Health Awards

AbbVie announces the introduction of an interim commercial offer to the NHS for HUMIRA® (adalimumab) from 1st November 2018

Press Releases   •   Oct 18, 2018 14:33 BST

AbbVie announces the introduction of an interim commercial offer to the NHS for HUMIRA® (adalimumab) from 1st November 2018

AbbVie’s response* to NHS England’s announcement to switching to new versions of adalimumab

Press Releases   •   Oct 16, 2018 13:22 BST

AbbVie today (16th October 2018) welcomes the intention expressed by NHS England to maintain HUMIRA® (adalimumab); a specialised biologic medicine for treating a number of inflammatory conditions, as an ongoing treatment option for physicians and patients, as part of the adalimumab tendering strategy, which will start on 1st December 2018.

AbbVie UK publishes 2017 transparency data

AbbVie UK publishes 2017 transparency data

Press Releases   •   Jun 29, 2018 12:25 BST

AbbVie annual transparency publication of transfer of value data to healthcare professionals, healthcare organisations and patient organisation goes live 29 June 2018.

AbbVie UK Launches Third Annual ‘Big Ideas for Better Health’ Awards

AbbVie UK Launches Third Annual ‘Big Ideas for Better Health’ Awards

Press Releases   •   May 22, 2018 05:00 BST

-Awards celebrate forward-thinking individuals and teams who are championing innovation and supporting the NHS to become more resilient and sustainable -Independent judging panel led by Patients Association -Winning teams receive £3000 bursary to spread their work

AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

Press Releases   •   May 02, 2018 10:10 BST

• Application supported by four pivotal Phase 3 trials evaluating patients with moderate to severe plaque psoriasis (refs 1-3) • Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit (ref 4) and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing

New Presentation, HUMIRA® (adalimumab) 20 mg/0.2 mL for Injection in Pre-filled Syringe (PFS) Launched for Paediatric Patients, together with the Introduction of Fixed Weight Dosing

Press Releases   •   Mar 29, 2018 16:06 BST

Maidenhead, UK, 29th March 2018 – AbbVie a global research and development-based biopharmaceutical company, today announced the launch of HUMIRA® (adalimumab) 20 mg/0.2 mL presentation. The presentation is designed for injection in a pre-filled syringe specifically in paediatric patients for approved indications.

AbbVie’s Duodopa® (levodopa-carbidopa intestinal gel) recommended for use within NHS Wales

Press Releases   •   Mar 27, 2018 09:46 BST

All Wales Medicines Strategy Group (AWMSG) recommends levodopa-carbidopa intestinal gel as an option for the treatment of advanced Parkinson’s in patients not eligible for deep brain stimulation

NEARLY TWO THIRDS PUT OFF SEEING DOCTORS DUE TO DIAGNOSIS FEARS – NEW QUIZ LAUNCHED TODAY TO UNDERSTAND WHY

NEARLY TWO THIRDS PUT OFF SEEING DOCTORS DUE TO DIAGNOSIS FEARS – NEW QUIZ LAUNCHED TODAY TO UNDERSTAND WHY

Press Releases   •   Feb 15, 2018 00:01 GMT

New ‘Crush Your FOFO’ quiz will help experts and the public better understand FOFO which is preventing people from seeking medical advice

NICE recommends AbbVie’s HUMIRA® (adalimumab) for treatment of non-infectious uveitis

Press Releases   •   Feb 12, 2018 13:42 GMT

NICE publishes guidance recommending AbbVie’s HUMIRA® (adalimumab) as an option for treating eligible adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids

Response To Announcement Of NHS England’s Plans To Be First In The World To Eliminate Hepatitis C

Press Releases   •   Jan 26, 2018 08:46 GMT

MAIDENHEAD, UK, January 28, 2017 – We welcome NHS England’s announcement of their plans towards the elimination of hepatitis C in England and we are encouraged to see a commitment being made for the long-term.

AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

Press Releases   •   Dec 14, 2017 00:01 GMT

Phase III MURANO results presented for the first time as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta